OTREXUP (methotrexate) for subcutaneous injection Antares Pharma announced the availability of Otrexup (methotrexate for subcutaneous injection) for once-weekly self-administration with a single-dose ...

“OTREXUP provides an attractive new option that may benefit patients who have had an inadequate response to or are intolerant of oral MTX,” said Paul K. Wotton, PhD, President and Chief Executive ...

Antares Pharma, Inc. (NASDAQ: ATRS) today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate (MTX) ...

EWING, N.J.--(BUSINESS WIRE)-- Antares Pharma, Inc. (NAS: ATRS) today announced that data from a pivotal clinical trial of OTREXUP™ (methotrexate) for subcutaneous injection were selected for live, ...

Antares Pharma announced that the FDA has approved Otrexup (methotrexate) injection, the first subcutaneous (SC) methotrexate for once-weekly self-administration with a single-dose, disposable ...

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for OTREXUP™, a ...

Antares Pharma announced its first-quarter results Wednesday morning but failed to impress the market. Shares were down around 3% in midday trading. Here are the highlights from the company's results.

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced the issuance of U.S. Patents RE44846 and RE44847. These patents are reissued ...

Antares ( ATRS) is preparing to launch Otrexup in January 2014; it is the first product it has ever introduced and investor attention is keenly focused on the launch. This report is not a ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: Otrexup ...

Antares Pharma didn't impress the market with its Q1 results, but a pending Food and Drug Administration decision on Otrexup might be a game changer for this small biotech. Results Antares reported a ...